PaxMedica (NASDAQ: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of autism spectrum disorder (“ASD”) and other serious conditions, today announced its Gold Sponsorship of The BRAIN Foundation’s esteemed Synchrony Symposia 2023. The globally recognized event serves as a catalyst for translational research in … Continue reading InvestorNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) to Serve as Gold Sponsor of Synchrony Symposia 2023